MedCity News January 15, 2024
Kevin Sayer would love to bring his company’s Dexcom G7 continuous glucose monitor to more people and more quickly. But despite being CEO of a successful device company, he feels frustrated from time to time about how and what the U.S. health system will pay for.
Dexcom’s CEO has already created some magic for investors.
Last Monday, the maker of continuous glucose monitors for people battling diabetes announced its preliminary fourth-quarter financial results stating that it expects to garner at least $1.03 billion in the quarter that ended December 31, a 26% jump over the same period a year ago.
But the company’s CEO — Kevin Sayer, a diabetic himself — is not taking any victory laps. In an interview...
Today's Sponsors
Today's Sponsor